{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:29:46Z","timestamp":1786120186212,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/iae.0b013e318229b220","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T12:12:06Z","timestamp":1312459926000},"page":"468-472","source":"Crossref","is-referenced-by-count":22,"title":["INTRAVITREAL ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO OCULAR HISTOPLASMOSIS SYNDROME"],"prefix":"10.1097","volume":"32","author":[{"given":"Jared S","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler A","family":"Fick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D","family":"Saggau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210616","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0161-6420(84)34113-6","article-title":"Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis.","volume":"91","author":"Olk","year":"1984","journal-title":"Ophthalmology"},{"key":"R2-6-20210616","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00006982-198808040-00001","article-title":"Subfoveal neo-vascularization in the ocular histoplasmosis syndrome: a natural history study.","volume":"8","author":"Kleiner","year":"1988","journal-title":"Retina"},{"key":"R3-6-20210616","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/archopht.1987.01060110045029","article-title":"Results of a randomized clinical trial. Macular Photocoagulation Study Group.","volume":"105","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"R4-6-20210616","first-page":"1109","article-title":"Macular Photocoagulation Study Group.","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R5-6-20210616","first-page":"56","article-title":"Results from clinical trials for lesions secondary to ocular histoplasmosis or idiopathic causes. Macular Photocoagulation Study Group.","volume":"1","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"R6-6-20210616","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archopht.122.11.1597","article-title":"Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST report no. 9.","volume":"122","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R7-6-20210616","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00006982-200306000-00003","article-title":"Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome.","volume":"3","author":"Busquets","year":"2003","journal-title":"Retina"},{"key":"R8-6-20210616","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ophtha.2004.02.014","article-title":"Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study.","volume":"9","author":"Rosenfeld","year":"2004","journal-title":"Ophthalmology"},{"key":"R9-6-20210616","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/ICU.0b013e328329d173","article-title":"Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.","volume":"3","author":"Ciulla","year":"2009","journal-title":"Curr Opin Ophthalmol"},{"key":"R10-6-20210616","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ophtha.2010.04.016","article-title":"Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial.","volume":"1","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"key":"R11-6-20210616","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.2008.145391","article-title":"Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.","volume":"93","author":"Ruiz-Moreno","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R12-6-20210616","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/bjo.2008.143461","article-title":"Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks.","volume":"93","author":"Wiegand","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R13-6-20210616","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ajo.2009.04.026","article-title":"Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.","volume":"4","author":"Sawa","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R14-6-20210616","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/IAE.0b013e31815e9834","article-title":"Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization.","volume":"9","author":"Adan","year":"2007","journal-title":"Retina"},{"key":"R15-6-20210616","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0b013e3181babdf1","article-title":"Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.","volume":"10","author":"Ehrlich","year":"2009","journal-title":"Retina"},{"key":"R16-6-20210616","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2007.12.030","article-title":"Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis.","volume":"5","author":"Schadlu","year":"2008","journal-title":"Am J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-201203000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:13:14Z","timestamp":1786047194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-201203000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e318229b220","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}